“Advancements in Targeted Therapies and Diagnostic Innovations Driving Market Growth”
- A key trend in the global Extramammary Paget Disease (EMPD) market is the increasing focus on early diagnosis and precision medicine approaches. With EMPD being a rare and often misdiagnosed malignancy, advancements in dermatopathology, immunohistochemistry, and molecular diagnostics are significantly improving detection rates and enabling more accurate treatment decisions
- For instance, the use of HER2/neu testing has emerged as a critical tool in identifying patients who may benefit from targeted therapies, particularly trastuzumab-based regimens. Studies have shown HER2 positivity in a subset of EMPD patients, paving the way for precision oncology in this rare cancer segment
- Surgical interventions remain the cornerstone of treatment, with Mohs micrographic surgery leading as the preferred method due to its ability to remove cancerous tissues while preserving healthy surrounding tissue. This technique is associated with lower recurrence rates, especially in high-risk anatomical areas like the vulva or perianal region
- The rise in topical chemotherapy agents such as imiquimod and 5-fluorouracil, particularly for patients with in-situ EMPD or those unfit for surgery, is expanding non-invasive treatment options. These treatments offer acceptable local control while minimizing systemic side effects and cosmetic damage
- Moreover, the market is experiencing increased clinical research activity focused on immunotherapies and checkpoint inhibitors, especially for metastatic or recurrent EMPD. Agents targeting the PD-1/PD-L1 pathway are under evaluation, driven by the tumor’s immune microenvironment characteristics
- As awareness grows among dermatologists and oncologists about EMPD's distinctive clinical presentation and management challenges, global collaborations and rare cancer registries are playing an important role in accelerating research, improving epidemiological understanding, and encouraging orphan drug development
- The demand for specialized diagnostic and treatment pathways for EMPD is expected to surge, supported by expanding access to cancer care, increased investment in rare disease R&D, and the emergence of multidisciplinary treatment frameworks in tertiary care centers worldwide
